File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/TP.0000000000001883
- Scopus: eid_2-s2.0-85025427208
- PMID: 28731907
- WOS: WOS:000411270000026
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Oral nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B with Preexisting rt204 Mutation
Title | Oral nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B with Preexisting rt204 Mutation |
---|---|
Authors | |
Issue Date | 2017 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com |
Citation | Transplantation, 2017 How to Cite? |
Abstract | BACKGROUND: There is currently limited data regarding the use of oral antiviral therapy alone without HBIG for CHB patients with preexisting LAM-resistance (LAM-R) undergoing liver transplantation. METHODS: This is a cohort study determining the effectiveness and long-term outcome in this group of patients. RESULTS: Fifty-seven consecutive CHB patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM undergoing liver transplantation were included, with a median follow-up of 73 months. Fifty-five (96.5%) patients received a regimen that included the use of nucleotide analogs. The cumulative rate of HBsAg seroclearance at 1, 5, and 10 years was 82%, 88%, and 91% respectively. At the time of transplantation, 39 (72%) patients had detectable HBV DNA, with a median of 4.5 log copies/mL. The cumulative rate of HBV undetectability was 91% at 1 year, increasing to 100% by 5 years. After 1 year of liver transplantation, over 90% of patients had undetectable HBV DNA, and from 8 years onwards, 100% had undetectable HBV DNA. The overall long-term survival was excellent, with a 12-year survival of 87%. There was no HBV-related graft loss, and no retransplantation or deaths due to HBV reactivation. CONCLUSION: Oral antiviral therapy alone without HBIG is highly effective in preventing HBV reactivation and graft loss from recurrent hepatitis B after liver transplantation in patients with preexisting lamivudine resistance HBV. The long-term outcome was excellent, with survival of 87% at 12 years after transplantation, without any mortality related to HBV reactivation. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/243161 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.371 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Wong, CLT | - |
dc.contributor.author | Chok, KSH | - |
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Sin, SL | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Dai, WC | - |
dc.contributor.author | Ng, KCK | - |
dc.contributor.author | Ng, KTP | - |
dc.contributor.author | Man, K | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2017-08-25T02:50:54Z | - |
dc.date.available | 2017-08-25T02:50:54Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Transplantation, 2017 | - |
dc.identifier.issn | 0041-1337 | - |
dc.identifier.uri | http://hdl.handle.net/10722/243161 | - |
dc.description.abstract | BACKGROUND: There is currently limited data regarding the use of oral antiviral therapy alone without HBIG for CHB patients with preexisting LAM-resistance (LAM-R) undergoing liver transplantation. METHODS: This is a cohort study determining the effectiveness and long-term outcome in this group of patients. RESULTS: Fifty-seven consecutive CHB patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM undergoing liver transplantation were included, with a median follow-up of 73 months. Fifty-five (96.5%) patients received a regimen that included the use of nucleotide analogs. The cumulative rate of HBsAg seroclearance at 1, 5, and 10 years was 82%, 88%, and 91% respectively. At the time of transplantation, 39 (72%) patients had detectable HBV DNA, with a median of 4.5 log copies/mL. The cumulative rate of HBV undetectability was 91% at 1 year, increasing to 100% by 5 years. After 1 year of liver transplantation, over 90% of patients had undetectable HBV DNA, and from 8 years onwards, 100% had undetectable HBV DNA. The overall long-term survival was excellent, with a 12-year survival of 87%. There was no HBV-related graft loss, and no retransplantation or deaths due to HBV reactivation. CONCLUSION: Oral antiviral therapy alone without HBIG is highly effective in preventing HBV reactivation and graft loss from recurrent hepatitis B after liver transplantation in patients with preexisting lamivudine resistance HBV. The long-term outcome was excellent, with survival of 87% at 12 years after transplantation, without any mortality related to HBV reactivation. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com | - |
dc.relation.ispartof | Transplantation | - |
dc.rights | This is a non-final version of an article published in final form in (provide complete journal citation) | - |
dc.title | Oral nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B with Preexisting rt204 Mutation | - |
dc.type | Article | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Wong, CLT: wongtcl@hku.hk | - |
dc.identifier.email | Chok, KSH: chok6275@hku.hk | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.email | Dai, WC: daiwc@hku.hk | - |
dc.identifier.email | Ng, KCK: kkcng@hku.hk | - |
dc.identifier.email | Ng, KTP: ledodes@hku.hk | - |
dc.identifier.email | Man, K: kwanman@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Wong, CLT=rp01679 | - |
dc.identifier.authority | Chok, KSH=rp02110 | - |
dc.identifier.authority | Chan, ACY=rp00310 | - |
dc.identifier.authority | Cheung, TT=rp02129 | - |
dc.identifier.authority | Ng, KTP=rp01720 | - |
dc.identifier.authority | Man, K=rp00417 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1097/TP.0000000000001883 | - |
dc.identifier.pmid | 28731907 | - |
dc.identifier.scopus | eid_2-s2.0-85025427208 | - |
dc.identifier.hkuros | 274711 | - |
dc.identifier.volume | Epub ahead of print | - |
dc.identifier.isi | WOS:000411270000026 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0041-1337 | - |